DE10345837A1 - Verfahren zur Bestimmung einer Wirkstoffdosierung - Google Patents

Verfahren zur Bestimmung einer Wirkstoffdosierung Download PDF

Info

Publication number
DE10345837A1
DE10345837A1 DE10345837A DE10345837A DE10345837A1 DE 10345837 A1 DE10345837 A1 DE 10345837A1 DE 10345837 A DE10345837 A DE 10345837A DE 10345837 A DE10345837 A DE 10345837A DE 10345837 A1 DE10345837 A1 DE 10345837A1
Authority
DE
Germany
Prior art keywords
dollar
specific
data
pbpk model
model
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10345837A
Other languages
English (en)
Inventor
Walter Schmitt
Stefan Willmann
Edgar Diesel
Ingmar Dorn
Jens Burmeister
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Technology Services GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Technology Services GmbH filed Critical Bayer Technology Services GmbH
Priority to DE10345837A priority Critical patent/DE10345837A1/de
Priority to AU2004278478A priority patent/AU2004278478A1/en
Priority to CA002540789A priority patent/CA2540789A1/en
Priority to JP2006529998A priority patent/JP2007510970A/ja
Priority to PCT/EP2004/010560 priority patent/WO2005033334A2/de
Priority to EP04765437A priority patent/EP1671250A2/de
Priority to US10/947,982 priority patent/US20050074803A1/en
Publication of DE10345837A1 publication Critical patent/DE10345837A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Evolutionary Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Es wird ein Verfahren zur Bestimmung der Dosierung von mindestens einem Wirkstoff auf Basis einer genetischen Analyse beschrieben. Das Verfahren umfasst die folgenden Schritte: DOLLAR A a) Analyse (101) von spezifischen Gensequenzen, mittels eines gensequenz-spezifischen Analysengerätes, insbesondere eines sequenz-spezifischen Sensors, oder Bestimmung der Expression von Proteinen entweder über RNA Transkription mittels quantitativer RNA-spezifischer Nachweismethoden oder direkte Messeung der Proteinexpression durch ein Protein-Analysegerät, DOLLAR A b) Zuordnung der Gensequenzen zu physiologischen Funktionen des menschlichen oder tierischen Körpers, insbesondere solchen physiologischen Funktionen, die Einfluss auf den Abbau, auf die Aufnahme, auf die Abgabe oder auf das Verteilungsverhalten des Wirkstoffes im Körper haben, DOLLAR A c) Weitergabe der genetischen und der Zuordnungsdaten an ein physiologie-basiertes pharmakokinetisches Modell (PBPK-Modell) (108), DOLLAR A d) Eingabe von Wirkstoff-spezifischen Daten in das PBPK-Modell (108), DOLLAR A e) Eingabe von charakteristischen Patientendaten, gegebenenfalls aus direkten Messungen am Körper, DOLLAR A f) Berechnung von für das PBPK-Modell notwendigen physiologischen Einflussparametern aus den Patientendaten unter Verwendung von in der Wissensdatenbank enthaltenen Informationen und Weitergabe der Parameter an das PBPK-Modell (108), DOLLAR A g) Berechnung der individuellen Dosis aus den Daten nach den Schritten c), d) und f) unter Verwendung des PBPK-Modells (108).
DE10345837A 2003-10-02 2003-10-02 Verfahren zur Bestimmung einer Wirkstoffdosierung Withdrawn DE10345837A1 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE10345837A DE10345837A1 (de) 2003-10-02 2003-10-02 Verfahren zur Bestimmung einer Wirkstoffdosierung
AU2004278478A AU2004278478A1 (en) 2003-10-02 2004-09-21 Method for determining an active ingredient dosage
CA002540789A CA2540789A1 (en) 2003-10-02 2004-09-21 Method for determining an active ingredient dosage
JP2006529998A JP2007510970A (ja) 2003-10-02 2004-09-21 活性物質の投与量の決定方法
PCT/EP2004/010560 WO2005033334A2 (de) 2003-10-02 2004-09-21 Verfahren zur bestimmung einer wirkstoffdosierung
EP04765437A EP1671250A2 (de) 2003-10-02 2004-09-21 Verfahren zur bestimmung einer wirkstoffdosierung
US10/947,982 US20050074803A1 (en) 2003-10-02 2004-09-23 Method for determining an active agent dose

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10345837A DE10345837A1 (de) 2003-10-02 2003-10-02 Verfahren zur Bestimmung einer Wirkstoffdosierung

Publications (1)

Publication Number Publication Date
DE10345837A1 true DE10345837A1 (de) 2005-04-21

Family

ID=34353270

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10345837A Withdrawn DE10345837A1 (de) 2003-10-02 2003-10-02 Verfahren zur Bestimmung einer Wirkstoffdosierung

Country Status (7)

Country Link
US (1) US20050074803A1 (de)
EP (1) EP1671250A2 (de)
JP (1) JP2007510970A (de)
AU (1) AU2004278478A1 (de)
CA (1) CA2540789A1 (de)
DE (1) DE10345837A1 (de)
WO (1) WO2005033334A2 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038645B2 (en) 2005-06-17 2011-10-18 Bayer Technology Services Gmbh Device for the time-controlled intravenous administering of the anesthetic propofol
US9095653B2 (en) 2004-03-04 2015-08-04 Bayer Intellectual Property Gmbh Method for the timed dosage of medicaments
WO2016102463A1 (en) 2014-12-23 2016-06-30 Bosteels Arnaud Combination of remifentanil and propofol

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8949032B2 (en) * 2002-03-29 2015-02-03 Genomatica, Inc. Multicellular metabolic models and methods
EP1958111A4 (de) * 2005-11-29 2009-07-08 Childrens Hosp Medical Center Optimierung und individualisierung der auswahl und dosierung von medikamenten
JP2007279999A (ja) * 2006-04-06 2007-10-25 Hitachi Ltd 薬物動態解析システム及び方法
DE102006028232A1 (de) * 2006-06-20 2007-12-27 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis
WO2008081830A1 (ja) * 2006-12-27 2008-07-10 Nemoto Kyorindo Co., Ltd. 薬液注入装置および薬液注入方法
US20080221847A1 (en) * 2007-03-09 2008-09-11 Frederique Fenetteau Method of developing a pharmacokinetic profile of a xenobiotic disposition in a mammalian tissue
CN101945613B (zh) * 2008-02-18 2014-08-13 皇家飞利浦电子股份有限公司 为患者用药
US20100125782A1 (en) * 2008-11-14 2010-05-20 Howard Jay Snortland Electronic document for automatically determining a dosage for a treatment
US20100125421A1 (en) * 2008-11-14 2010-05-20 Howard Jay Snortland System and method for determining a dosage for a treatment
EP2538360A1 (de) * 2011-06-16 2012-12-26 Koninklijke Philips Electronics N.V. Verfahren zur Vorhersage eines Blutverdünnungsrisikowerts
EP3027763B1 (de) * 2013-07-29 2018-05-30 The Regents of The University of California Steuerungstechnologieplattform für ein echtzeit-feedback-system mit dynamisch wechselnden stimulationen
WO2015017798A2 (en) 2013-08-02 2015-02-05 CRIXlabs, Inc. Method and system for predicting spatial and temporal distributions of therapeutic substance carriers
WO2019104101A1 (en) * 2017-11-21 2019-05-31 Verisim Life Inc. Systems and methods for full body circulation and drug concentration prediction
CN113140321B (zh) * 2021-05-20 2023-12-19 中国药科大学 运用PK-sim预测异甘草酸镁在人体中暴露浓度的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
AUPR446701A0 (en) * 2001-04-18 2001-05-17 Gene Stream Pty Ltd Transgenic mammals for pharmacological and toxicological studies
US20030104428A1 (en) * 2001-06-21 2003-06-05 President And Fellows Of Harvard College Method for characterization of nucleic acid molecules

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9095653B2 (en) 2004-03-04 2015-08-04 Bayer Intellectual Property Gmbh Method for the timed dosage of medicaments
US8038645B2 (en) 2005-06-17 2011-10-18 Bayer Technology Services Gmbh Device for the time-controlled intravenous administering of the anesthetic propofol
WO2016102463A1 (en) 2014-12-23 2016-06-30 Bosteels Arnaud Combination of remifentanil and propofol

Also Published As

Publication number Publication date
JP2007510970A (ja) 2007-04-26
US20050074803A1 (en) 2005-04-07
CA2540789A1 (en) 2005-04-14
EP1671250A2 (de) 2006-06-21
AU2004278478A1 (en) 2005-04-14
WO2005033334A2 (de) 2005-04-14
WO2005033334A3 (de) 2005-09-29

Similar Documents

Publication Publication Date Title
Frank et al. Hippocampal plasticity across multiple days of exposure to novel environments
Sekerli et al. Estimating action potential thresholds from neuronal time-series: new metrics and evaluation of methodologies
Davis et al. Operational standards for CASA instruments
Jacobs et al. Comparative morphology of gigantopyramidal neurons in primary motor cortex across mammals
Youngentob et al. Predicting odorant quality perceptions from multidimensional scaling of olfactory bulb glomerular activity patterns.
JP2010539490A5 (de)
WO2018158083A1 (de) Verfahren und anordnung zum ermitteln einer nicht-therapeutischen behandlung des mundraums
WO2005033334A3 (de) Verfahren zur bestimmung einer wirkstoffdosierung
JP2007510970A5 (de)
EP2032036A2 (de) Anordnung und verfahren zur identifizierung von personen
Madea et al. Tasks of research in forensic medicine–different study types in clinical research and forensic medicine
JP2013531313A (ja) 複雑ネットワークにおけるシステム全体の動特性の定量化のためのシステム
Shapiro Guidelines for developing and testing clinical decision rules
DE60016017T2 (de) Verfahren zum nachweis von progesteron in rohmilch
CN117438072A (zh) 一种用于生物反馈设备的数据库检测运算方法
Avrunin et al. Assessment of the diagnostic value of the method of computer olfactometry
EP1640888A2 (de) Verfahren zum Abschätzen und Überwachen des medizinischen Risikos einer Gesundheitsstörung bei einem Patienten
CN111588359B (zh) 一种新冠肺炎预警系统
US20180303378A1 (en) Predictive Disease Breath Database Systems and Methods
Bleich et al. Effects of tooth extraction on body condition and reproduction of mule deer
EP4560314A1 (de) Verfahren und vorrichtung zur hochauflösenden räumlichen und zeitlichen kartierung elektrophysiologischer dynamiken und transkriptionsprofile in intaktem hirngewebe
US20190034594A1 (en) Computer-based systems and methods for monitoring the heart muscle of a patient with comprehensive contextual oversight
Correia et al. 8287754 Disabling fibromyalgia in Brazil: an ecological study of social security benefits (2014–2024)
DE60203877T2 (de) Gerät zur diagnose und überwachung des zustands des vegetativen nervensystems sowie für die behandlung von krankheiten und leiden aufgrund von hormonstörungen
Birkhold A 4D imaging approach to monitor bone remodeling

Legal Events

Date Code Title Description
8130 Withdrawal